MCL Clinical Trials
1230 trials from ClinicalTrials.gov. Recruiting trials shown first.
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
COMPLETEDNCT00553644·PHASE2·National Cancer Institute (NCI)·53 enrolled
BortezomibLaboratory Biomarker AnalysisLenalidomide
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
COMPLETEDNCT00561418·PHASE1·Ohio State University Comprehensive Cancer Center·23 enrolled
vorinostatCorrelative studies
Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma
COMPLETEDNCT00401817·PHASE2·Weill Medical College of Cornell University·11 enrolled
BevacizumabRituximabCHOP
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
WITHDRAWNNCT00621036·PHASE2·University of Texas Southwestern Medical Center
autologous immunoglobulin idiotype-KLH conjugate vaccinesargramostimmethotrexatethioteparadiation therapy
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
COMPLETEDNCT00577278·PHASE2·City of Hope Medical Center·41 enrolled
rituximabfludarabine phosphatemelphalansirolimustacrolimus+4 more
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
COMPLETEDNCT00538850·PHASE3·INSYS Therapeutics Inc·130 enrolled
Fentanyl sublingual sprayPlacebo
Studying Fentanyl in Patients With Cancer
TERMINATEDNCT00899951·Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·2 enrolled
fentanyl citratepharmacological study
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
TERMINATEDNCT00543582·PHASE2·Mirati Therapeutics Inc.·23 enrolled
MGCD0103 and Azacitidine
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
COMPLETEDNCT00646139·PHASE1·Roswell Park Cancer Institute·7 enrolled
Src kinase inhibitor KX2-391immunoenzyme techniquepharmacological study
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
COMPLETEDNCT00561756·PHASE1·Memorial Sloan Kettering Cancer Center·8 enrolled
plasmid DNA vaccine therapyflow cytometryimmunoenzyme technique
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
TERMINATEDNCT00904514·National Institutes of Health Clinical Center (CC)·241 enrolled
gene expression analysismicroarray analysismutation analysispolymerase chain reactionflow cytometry+2 more
In-Vivo Activated T-Cell Depletion to Prevent GVHD
TERMINATEDNCT00594308·NA·Indiana University·10 enrolled
CyclophosphamideFludarabineCyclosporineMycophenolate mofetilBasiliximab
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
COMPLETEDNCT00609869·PHASE2·H. Lee Moffitt Cancer Center and Research Institute·29 enrolled
LenalidomideRituximab
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
COMPLETEDNCT00547534·PHASE2·University of Rochester·31 enrolled
bortezomibbendamustinerituximab
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
WITHDRAWNNCT00521261·PHASE1·Barbara Ann Karmanos Cancer Institute
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
COMPLETEDNCT00536978·PHASE2·M.D. Anderson Cancer Center·22 enrolled
ARA-CBCNUCampath-1HCyclophosphamideEtoposide+8 more
Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma
WITHDRAWNNCT00541424·M.D. Anderson Cancer Center
PET/CT Scanning
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
COMPLETEDNCT01093586·PHASE2·Case Comprehensive Cancer Center·14 enrolled
double-unit umbilical cord blood transplantationcytogenetic analysisbone marrow aspirationfluorescence in situ hybridizationbusulfan+7 more
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
UNKNOWNNCT00637637·PHASE2·Oncology Institute of Southern Switzerland·60 enrolled
indinavir sulfateritonavirradiation therapy
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
COMPLETEDNCT00474929·PHASE1 / PHASE2·Mayo Clinic·103 enrolled
RAD001Sorafenib
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
COMPLETEDNCT00516412·PHASE2·Swiss Cancer Institute·35 enrolled
everolimusmolecular response by PCR
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
WITHDRAWNNCT00499668·NA·Vanderbilt-Ingram Cancer Center
aprepitantondansetron hydrochloride
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
COMPLETEDNCT00621452·PHASE1·Fred Hutchinson Cancer Center·12 enrolled
therapeutic autologous lymphocytescyclophosphamidealdesleukinpolymerase chain reactiongene rearrangement analysis+6 more
Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma
COMPLETEDNCT00589381·PHASE1·National Institutes of Health Clinical Center (CC)·30 enrolled
fenretinide lipid matrix
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
COMPLETEDNCT00602693·PHASE1·Masonic Cancer Center, University of Minnesota·41 enrolled
umbilical cord blood transplantationAllopurinolfludarabine phosphateCyclophosphamideTotal body irradiation+2 more
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
UNKNOWNNCT00445497·PHASE3·Clatterbridge Centre for Oncology·400 enrolled
amoxicillin-clavulanate potassiumciprofloxacinpsychosocial assessment and carequality-of-life assessment
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
COMPLETEDNCT00472420·PHASE2·Hoffmann-La Roche·48 enrolled
rituximab [MabThera/Rituxan]First line chemotherapy
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
TERMINATEDNCT00847223·PHASE2·Lymphoma Study Association·11 enrolled
ZARNESTRA (Tipifarnib)
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
COMPLETEDNCT00740415·PHASE2·French Innovative Leukemia Organisation·39 enrolled
rituximabbortezomibdexamethasoneBendamustine
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
COMPLETEDNCT00509691·PHASE1·University of Louisville·20 enrolled
cytomegalovirus pp65-specific cytotoxic T lymphocytespolymerase chain reactiondiagnostic laboratory biomarker analysisflow cytometryimmunologic technique